Off-Label Use of Contrast Media: Practical Aspects

  • Peter Reimer
  • Rolf Vosshenrich
Part of the Medical Radiology book series (MEDRAD)


The chapter deals with the practical aspects and extent of off-label use of medicines, particularly the off-label use of contrast agents. A number of MR and US contrast agents lack approval for some age groups or indications. Using a contrast agent off-label can be avoided in most cases by checking the label/Summary of Product Characteristics and using another contrast agent which is approved. The physician prescribing the contrast agent must be aware of the contrast agent label/Summary of Product Characteristics and is responsible for the administration of the contrast agent in accordance with current medico-legal regulations.


Contrast Agent Gadopentetate Dimeglumine Gadolinium Chelate Gadobenate Dimeglumine Gadoxetic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



European Union


Marketing Authorization Holder


Magnetic Resonance


Magnetic Resonance Imaging


Summary of Product Characteristics




  1. Askin DF (2006) Off-label therapies for newborns. Miracles or mistakes? AWHONN Lifelines 10:160–162PubMedCrossRefGoogle Scholar
  2. Barbui C, Ciuna A, Nose M et al (2004) Off-label and non-classical prescriptions of antipsychotic agents in ordinary in-patient practice. Acta Psychiatr Scand 109:275–278PubMedCrossRefGoogle Scholar
  3. Bazzano AT, Mangione-Smith R, Schonlau M et al (2009) Off-label prescribing to children in the United States outpatient setting. Acad Pediatr 9:81–88PubMedCrossRefGoogle Scholar
  4. Conroy S (2002) Unlicensed and off-label drug use: issues and recommendations. Paediatr Drugs 4:353–359PubMedGoogle Scholar
  5. Cras A, Conscience MA, Rajzbaum G et al (2007) Off-label prescribing in a French hospital. Pharm World Sci 29:97–100PubMedCrossRefGoogle Scholar
  6. Dresser R (2008) Off-label indications for medication use and the published literature. JAMA 300:1411–1412Google Scholar
  7. Gavrilov V, Lifshitz M, Levy J et al (2000) Unlicensed and off-label medication use in a general pediatrics ambulatory hospital unit in Israel. Isr Med Assoc J 2:595–597PubMedGoogle Scholar
  8. Haw C, Stubbs J (2005) A survey of off-label prescribing for inpatients with mild intellectual disability and mental illness. J Intellect Disabil Res 49:858–864PubMedCrossRefGoogle Scholar
  9. Heinemann AK, Lollgen N (2007) Off-label-use of contrast media. ROFO 179:867–868PubMedCrossRefGoogle Scholar
  10. Hsu B, Brazelton T (2009) Off-label medication use in an academic hospital pediatric critical care unit. WMJ 108:343–348PubMedGoogle Scholar
  11. Jain SS, Bavdekar SB, Gogtay NJ et al (2008) Off-label drug use in children. Indian J Pediatr 75:1133–1136PubMedCrossRefGoogle Scholar
  12. Jansen RM, Gouws C (2009) Clinical, legal and ethical implications of the intra-ocular (off-label) use of bevacizumab (avastin)–a South African perspective. S Afr Med J 99:446–449PubMedGoogle Scholar
  13. Kairuz TE, Gargiulo D, Bunt C et al (2007) Quality, safety and efficacy in the ‘off-label’ use of medicines. Curr Drug Saf 2:89–95PubMedCrossRefGoogle Scholar
  14. Knoester PD, Belitser SV, Deckers CL et al (2004) Diffusion of the new antiepileptic drug lamotrigine in Dutch clinical practice. Eur J Clin Pharmacol 60:751–758PubMedCrossRefGoogle Scholar
  15. Knopp MV, Lodemann M, Kage U et al (2001) Administration of MR contrast agents outside of approved indications (off-label use). Radiologe 41:296–302PubMedCrossRefGoogle Scholar
  16. Oguz SS, Kanmaz HG, Dilmen U (2012) Off-label and unlicensed drug use in neonatal intensive care units in Turkey: the old-inn study. Int J Clin Pharm 34:136–141PubMedCrossRefGoogle Scholar
  17. Olsson J, Kimland E, Pettersson S et al (2011) Paediatric drug use with focus on off-label prescriptions in Swedish outpatient care—a nationwide study. Acta Paediatr 100:1272–1275PubMedCentralPubMedCrossRefGoogle Scholar
  18. Pasquali SK, Hall M, Slonim AD et al (2008) Off-label use of cardiovascular medications in children hospitalized with congenital and acquired heart disease. Circ Cardiovasc Qual Outcomes 1:74–83PubMedCrossRefGoogle Scholar
  19. Poole SG, Dooley MJ (2004) Off-label prescribing in oncology. Support Care Cancer 12:302–305PubMedCrossRefGoogle Scholar
  20. Regan J, Alderson A (2003) Off-label” psychotropic medication use in children. Tenn Med 96:429–431PubMedGoogle Scholar
  21. Reimer P, Vosshenrich R (2008) Off-label use of contrast agents. Eur Radiol 18:1096–1101PubMedCrossRefGoogle Scholar
  22. Reimer P, Vosshenrich R (2013) Kontrastmittel in der Radiologie—Angiographie, CT, MR und US: Aktuelle Zulassungen, Empfehlungen und Sicherheitshinweise. RadiologeGoogle Scholar
  23. Roila F, Ballatori E, Labianca R et al (2009) Off-label prescription of antineoplastic drugs: an Italian prospective, observational, multicenter survey. Tumori 95:647–651PubMedGoogle Scholar
  24. Runge VM (2001) Safety of magnetic resonance contrast media. Top Magn Reson Imaging 12:309–314PubMedCrossRefGoogle Scholar
  25. Runge VM, Knopp MV (1999) Off-label use and reimbursement of contrast media in MR. J Magn Reson Imaging 10:489–495PubMedCrossRefGoogle Scholar
  26. Scheinfeld N (2004) Off-label uses and side effects of infliximab. J Drugs Dermatol 3:273–284PubMedGoogle Scholar
  27. Scheltema Beduin A, de Haan L (2010) Off-label second generation antipsychotics for impulse regulation disorders: a review. Psychopharmacol Bull 43:45–81PubMedGoogle Scholar
  28. Sox HC (2009) Evaluating off-label uses of anticancer drugs: time for a change. Ann Intern Med 150:353–354PubMedCrossRefGoogle Scholar
  29. Tafuri G, Trotta F, Leufkens HG et al (2009) Off-label use of medicines in children: can available evidence avoid useless paediatric trials? The case of proton pump inhibitors for the treatment of gastroesophageal reflux disease. Eur J Clin Pharmacol 65:209–216PubMedCrossRefGoogle Scholar
  30. Verhagen CC, Niezink AG, Engels YY et al (2008) Off-label use of drugs in pain medicine and palliative care: an algorithm for the assessment of its safe and legal prescription. Pain Pract 8:157–163PubMedCrossRefGoogle Scholar
  31. Weiss E, Hummer M, Koller D et al (2000) Off-label use of antipsychotic drugs. J Clin Psychopharmacol 20:695–698PubMedCrossRefGoogle Scholar
  32. Whitfield K, Huemer K-H, Winter D et al (2010) Compassionate use of interventions: results of a European Clinical Research Infrastructures Network (ECRIN) survey of ten European countries. Trials 11:104 (
  33. Winterfeld U, Le Heuzey MF, Acquaviva E et al (2009) Off-label use of psychotropic medications in pediatric wards: a prospective study. Arch Pediatr 16:1252–1260PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Institute of diagnostic and interventional RadiologyKlinikum Karlsruhe Academic Teaching Hospital of the University of FreiburgKarlsruheGermany
  2. 2.Praxis für moderne Schnittbild DiagnostikGöttingenGermany

Personalised recommendations